February 2008
Pharmaceutical Representative;Feb2008, Vol. 38 Issue 2, p8
The article offers news briefs in the pharmaceutical industry. Eisai Co. Ltd. has agreed to buy MGI Pharma Inc. for $3.9 billion. GlaxoSmithKline collaborated with OncoMed Pharmaceuticals Inc. for the discovery, development and marketing of novel antibody therapeutics for the treatment of cancer. The drug Vectibix has been approved by the European Commission as monotherapy for the treatment of epidermal growth factor receptor-expressing metastatic colorectal cancer.


Related Articles

  • Leading Indicators. Koroneos, George // Pharmaceutical Executive;Jan2008, Vol. 28 Issue 1, p17 

    The article offers news briefs related to the pharmaceutical industries. A U.S. Food and Drug Administration (FDA) advisory panel has disapproved Merck & Co. Inc.'s cholesterol-lowering drug Mevacor, which is up for over-the-counter drugs in December 2007. Bristol-Myers Squibb Co. has announced...

  • Eisai gaining cancer portfolio in $3.9 billion MGI acquisition.  // Medical Technology & Devices Week;12/17/2007, Vol. 5 Issue 49, p4 

    This article reports on an agreement that allows Eisai Co. Ltd. to acquire MGI Pharma Inc. in 2007. Analyst Christopher Raymond of Robert Baird & Co. said he was impressed by the offer of MGI. In addition, the company said that it had met with many of the leading companies in the pharmaceutical...

  • TOP STORIES.  // MondayMorning;12/17/2007, Vol. 15 Issue 50, p1 

    This section offers news briefs on the pharmaceutical industry. Eisai Co. Ltd. would buy U.S. biotech firm MGI Pharma Inc. for $3.9 billion in cash to strengthen its cancer pipeline, marking the largest overseas acquisition by a Japanese drugmaker. A U.S. Food and Drug Administration panel on...

  • COMPANY SPOTLIGHT - Eisai.  // PharmaWatch: Cancer;Jul2010, Vol. 9 Issue 7, p21 

    The article presents a corporate profile of Japanese pharmaceutical company Eisai Co. Ltd. The company is involved in the research, development, manufacture and sale of pharmaceutical products. It also manufactures food additives and pharmaceutical production machinery and equipment. It...

  • FDA Approves Eisai Sedative.  // Bioworld Week;12/22/2008, Vol. 16 Issue 51, p3 

    The article reports that the U.S. Food and Drugs Administration has approved the sedative-hypnotic drug Lusedra, which is introduced by the U.S.-based Eisai Corp., a wholly owned subsidiary of Eisai Co. Ltd. based in Tokyo, Japan. It notes that Aquavan was among the $3.9 billion acquisition of...

  • World Briefs.  // Pharmaceutical Technology;Mar2008, Vol. 32 Issue 3, p24 

    The article offers world briefs related to pharmaceutical industry. MGI Pharma Inc. was acquired by Tokyo, Japan-based Eisai Co. Ltd. for an amount of $3.9 billion. Amira Pharmaceuticals Inc. and GlaxoSmithKline are in agreement to create and commercialize FLAP (5-lipoxygenase activating...

  • Antibody Deal With GSK Netting OncoMed $1.4B.  // Bioworld Week;12/17/2007, Vol. 15 Issue 51, p3 

    The article reports on the deal between OncoMed Pharmaceuticals Inc. and GlaxoSmithKline for the discovery, development and commercialization of antibodies targeting cancer stem cells. Under the agreement, OncoMed will receive an upfront payment composed of cash and equity as well as potential...

  • SWOT Analysis.  // PharmaWatch: CNS;Mar2011, Vol. 10 Issue 3, p25 

    The article offers information on the strengths, weaknesses, opportunities, and threats (SWOT) analysis of Eisai Co. Ltd. It says that its strength lies in its acquisition of MGI Pharma Inc. that shifted their therapy area focus to their oncology portfolio, which is expected to be their largest...

  • CLINIC ROUNDUP.  // BioWorld Today;5/24/2007, Vol. 18 Issue 101, p9 

    The article provides updates on the pharmaceutical industry as of May 24, 2007. HUYA Bioscience International LLC and Chipscreen Biosciences Ltd. said a Phase I clinical trial has been initiated with Chidamide in China. MGI Pharma Inc. said its Aquavan Injection in patients undergoing...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics